SURGICAL-TREATMENT OF BRAIN METASTASES - CLINICAL AND COMPUTERIZED-TOMOGRAPHY EVALUATION OF THE RESULTS OF TREATMENT
SURGICAL-TREATMENT OF BRAIN METASTASES - CLINICAL AND COMPUTERIZED-TOMOGRAPHY EVALUATION OF THE RESULTS OF TREATMENT
复制标题
DOI：
10.1002/1097-0142(19850315)55:6
复制
发表时间：
1985-01-01
期刊：
影响因子：
6.2
通讯作者：
GALICICH, JH
中科院分区：
文献类型：
--
作者：
SUNDARESAN, N;GALICICH, JH
本文分析了1978年至1982年125例脑转移瘤患者的治疗结果，这些患者接受了手术治疗，术后有或无放射治疗。原发性肿瘤的主要部位包括肺（40%）、黑色素瘤-皮肤（11%）、肾（11%）、结肠（8%）、软组织肉瘤（8%）、乳腺（6%）和各种其他部位（15%）。在开颅手术时，63名患者（50%）的疾病被认为仅限于中枢神经系统。手术后，83例患者（66%）神经功能改善，26例（21%）功能障碍稳定。总的中位生存期为12个月，25%的患者存活2年。8例患者（12%）术后存活5年或更长时间。生存率随原发肿瘤部位、脑转移部位、全身性疾病程度和开颅手术时神经功能缺损而变化。在18个月至6年的随访期间，42例患者（34%）发生局部复发或其他脑转移灶。这些数据表明，尽管开颅术后放疗在选定的脑转移患者的初始治疗中非常有效，但鉴于长期生存者的高中枢神经系统复发率，需要研究替代疗法。Cancer 55：1382 - 1388，1985。
The results of treatment of brain metastases in a series of 125 patients who underwent surgery with or without postoperative radiation from 1978 through 1982 were analyzed. The major sites of primary tumor included the lung (40%), melanoma‐skin (11%), kidney (11%), colon (8%), soft tissue sarcoma (8%), breast (6%), and a variety of others (15%). At the time of craniotomy, disease was considered limited to the central nervous system in 63 patients (50%). After surgery, 83 patients (66%) were neurologically improved, and 26 (21%) had their deficits stabilized. The overall median survival was 12 months, and 25% lived 2 years. Eight patients (12%) are alive 5 years or more following surgery. Survival varied with site of primary tumor, location of brain metastasis, extent of systemic disease, and neurologic deficit at time of craniotomy. Over a follow‐up period ranging from 18 months to 6 years, 42 patients (34%) developed either local recurrences or other sites of brain metastases. These data suggest that although craniotomy followed by radiation is highly effective in the initial treatment of selected patients with brain metastases, alternate therapies require investigation in view of the high central nervous system relapse rate in long‐term survivors.Cancer55:1382‐1388, 1985.